Business
HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth
SANTA CLARA, Calif., May 05, 2025--HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth
About this update from Heartbeam, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/dd1104f3d639fb01da40135ba2bb57f3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/muB7AHrtMyju2OOqzx8pdA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/dd1104f3d639fb01da40135ba2bb57f3","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/dG9vyG4DgxIzZ3fvvZmFAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/dd1104f3d639fb01da40135ba2bb57f3","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Board expansion reflects Company’s commitment to leadership and innovation in remote cardiac monitoring","length":103,"tagName":"p","attribs":{}},{"type":"text","content":"SANTA CLARA, Calif., May 05, 2025--(BUSINESS WIRE)--HeartBeam, Inc., (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition.","length":467,"tagName":"p"},{"type":"text","content":"Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven track record of developing markets and launching disruptive medical technologies. His leadership has been instrumental as HeartBeam prepares to commercialize its groundbreaking 3D ECG technology, which captures the heart’s electrical signals in 3 non-coplanar directions and then synthesizes these signals into a 12-lead ECG.","length":503,"tagName":"p"},{"type":"text","content":"Rich Ferrari, Executive Chairman, Board of Directors of HeartBeam, commented, "Rob’s deep expertise in sales and go-to-market strategies perfectly complements the diverse skillset and experience of the Board and strengthens our strategic oversight as we move toward commercialization and long-term growth. We are confident that Rob’s perspective will be instrumental ...